[ADMA] ADMA Biologics Inc


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.5 Change: -0.1 (-2.17%)
Ext. hours: Change: 0 (0%)

chart ADMA

Refresh chart

Strongest Trends Summary For ADMA

ADMA is in the long-term down -58% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.7 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.2% Sales Growth - Q/Q0.94% P/E-1.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.78% ROE-108.07% ROI-50.92%
Current Ratio8.18 Quick Ratio7.67 Long Term Debt/Equity0.55 Debt Ratio0.28
Gross Margin37.25% Operating Margin-231.07% Net Profit Margin-247.78% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.46 M Cash From Investing Activities-6.87 M Cash From Operating Activities-4.22 M Gross Profit590 K
Net Profit-3.61 M Operating Profit-3.2 M Total Assets33.93 M Total Current Assets30.98 M
Total Current Liabilities3.79 M Total Debt15.09 M Total Liabilities20.5 M Total Revenue1.5 M
Technical Data
High 52 week5.44 Low 52 week2.06 Last close5.44 Last change0.37%
RSI64.6 Average true range0.32 Beta0.52 Volume94.85 K
Simple moving average 20 days8.6% Simple moving average 50 days10.55% Simple moving average 200 days49.85%
Performance Data
Performance Week9.02% Performance Month12.86% Performance Quart39.85% Performance Half77.78%
Performance Year41.3% Performance Year-to-date69.47% Volatility daily2.91% Volatility weekly6.5%
Volatility monthly13.33% Volatility yearly46.17% Relative Volume814.37% Average Volume124.83 K
New High New Low


2020-06-01 09:44:01 | Are Options Traders Betting on a Big Move in ADMA Biologics ADMA Stock?

2020-05-27 07:00:10 | ADMA Biologics to Participate in Jefferies Virtual Healthcare Conference

2020-05-21 07:00:10 | ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients

2020-05-07 10:30:42 | ADMA Biologics Inc ADMA Q1 2020 Earnings Call Transcript

2020-05-07 10:22:08 | Edited Transcript of ADMA earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-07 08:42:00 | CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

2020-05-07 07:35:13 | ADMA Biologics Provides Corporate Update on Supply Chain Robustness and Recent Accomplishments

2020-05-06 20:15:12 | Adma Biologics ADMA Reports Q1 Loss, Misses Revenue Estimates

2020-05-06 16:05:10 | ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

2020-05-01 06:13:58 | Investors Who Bought ADMA Biologics NASDAQ:ADMA Shares Five Years Ago Are Now Down 60%

2020-04-29 07:00:10 | ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020

2020-03-17 06:12:57 | US$11.00: That's What Analysts Think ADMA Biologics, Inc. Is Worth After Its Latest Results

2020-03-13 01:16:42 | Edited Transcript of ADMA earnings conference call or presentation 12-Mar-20 8:30pm GMT

2020-03-12 16:05:10 | ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

2020-03-12 14:30:00 | ADMA Biologics, Inc. to Host Earnings Call

2020-03-05 06:59:10 | ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

2020-03-03 07:00:10 | ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

2020-02-24 07:00:10 | ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

2020-02-13 05:07:53 | Adam Grossman Is The Co-Founder of ADMA Biologics, Inc. NASDAQ:ADMA And They Just Spent US$300k On Shares

2020-02-11 16:20:10 | ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

2020-02-07 07:32:45 | The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

2020-02-06 20:41:07 | ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock

2020-02-06 16:06:44 | ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

2020-02-06 05:53:58 | When Will ADMA Biologics, Inc. NASDAQ:ADMA Become Profitable?

2020-01-09 07:00:10 | ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

2020-01-07 07:00:10 | ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

2019-12-23 05:36:41 | Have Insiders Been Buying ADMA Biologics, Inc. NASDAQ:ADMA Shares?

2019-12-17 07:08:10 | ADMA Biologics Added to NASDAQ Biotechnology Index

2019-12-14 20:04:31 | Hedge Funds Have Never Been More Bullish On ADMA Biologics Inc ADMA

2019-11-13 07:08:00 | ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

2019-11-08 05:33:22 | Here's Why ADMA Biologics NASDAQ:ADMA Can Afford Some Debt

2019-11-06 17:02:00 | ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

2019-11-04 07:08:00 | ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

2019-10-28 15:05:00 | Publicly traded biotechnology company to add 100 jobs in South Florida

2019-10-22 07:48:05 | ADMA Biologics Named Company of the Year by BioFlorida

2019-10-21 07:48:05 | ADMA Biologics Announces First Commercial Sales of ASCENIV™

2019-10-17 07:29:05 | ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

2019-10-09 11:08:48 | Should You Worry About ADMA Biologics, Inc.'s NASDAQ:ADMA CEO Salary Level?

2019-10-07 07:08:00 | ADMA Biologics Announces Data Presented at IDWeek 2019

2019-10-03 07:08:00 | ADMA Biologics Announces Poster Presentation at IDWeek 2019

2019-09-23 07:08:00 | ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

2019-09-09 14:54:50 | What Kind Of Investor Owns Most Of ADMA Biologics, Inc. NASDAQ:ADMA?

2019-08-22 07:48:00 | ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

2019-08-08 07:51:08 | Breakeven On The Horizon For ADMA Biologics, Inc. NASDAQ:ADMA

2019-08-08 07:08:00 | ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

2019-07-08 08:22:05 | ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

2019-06-27 09:30:13 | Did ADMA Biologics, Inc. NASDAQ:ADMA Insiders Buy Up More Shares?

2019-06-27 09:28:19 | How Many ADMA Biologics, Inc. NASDAQ:ADMA Shares Did Insiders Buy, In The Last Year?

2019-06-18 16:35:33 | ADMA Biologics: Selloff Creates Buying Opportunity

2019-06-06 07:25:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors